{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:16:11Z","timestamp":1789658171165,"version":"4.0.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.amjcard.2012.06.014","type":"journal-article","created":{"date-parts":[[2012,8,23]],"date-time":"2012-08-23T23:18:27Z","timestamp":1345763907000},"page":"S32-S38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"S","title":["The Potential of Biomarkers in Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"110","author":[{"given":"Jean-Luc","family":"Cracowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno H.","family":"Leuchte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2012.06.014_bib1","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2012.06.014_bib2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1183\/09031936.05.00075305","article-title":"Goal-oriented treatment and combination therapy for pulmonary arterial hypertension","volume":"26","author":"Hoeper","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjcard.2012.06.014_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2012.06.014_bib4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/469156a","article-title":"Bring on the biomarkers","volume":"469","author":"Poste","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.amjcard.2012.06.014_bib5","series-title":"An Introduction to Medical Statistics","first-page":"308","author":"Bland","year":"2000"},{"key":"10.1016\/j.amjcard.2012.06.014_bib6","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1056\/NEJMp038136","article-title":"Novel risk markers and clinical practice","volume":"349","author":"Manolio","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib7","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1056\/NEJMp068249","article-title":"The limitations of risk factors as prognostic tools","volume":"355","author":"Ware","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib8","first-page":"691","article-title":"The utility of troponin measurement to detect myocardial infarction: review of the current findings","volume":"6","author":"Daubert","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.amjcard.2012.06.014_bib9","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension","volume":"351","author":"Farber","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1183\/09031936.00160307","article-title":"Biomarkers in pulmonary hypertension","volume":"32","author":"Warwick","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjcard.2012.06.014_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1742-1241.2009.02117.x","article-title":"Biomarkers in pulmonary arterial hypertension","volume":"162","author":"Rafeq","year":"2009","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.amjcard.2012.06.014_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1742-1241.2010.02598.x","article-title":"Clinical perspective: biomarkers in pulmonary arterial hypertension","volume":"169","author":"Heresi","year":"2011","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.amjcard.2012.06.014_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/(SICI)1096-9896(199807)185:3<313::AID-PATH93>3.0.CO;2-8","article-title":"High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension","volume":"185","author":"Mason","year":"1998","journal-title":"J Pathol"},{"key":"10.1016\/j.amjcard.2012.06.014_bib16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1096\/fj.04-3223fje","article-title":"Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension","volume":"19","author":"Pullamsetti","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.amjcard.2012.06.014_bib17","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1161\/01.ATV.0000168414.06853.f0","article-title":"Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension","volume":"25","author":"Kielstein","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2012.06.014_bib18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1164\/ajrccm.158.3.9802066","article-title":"Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension","volume":"158","author":"Kaneko","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1378\/chest.111.1.44","article-title":"Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis","volume":"111","author":"Riley","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2012.06.014_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1042\/cs0970099","article-title":"Effect of nebulized epoprostenol (prostacyclin) on exhaled nitric oxide in patients with pulmonary hypertension due to congenital heart disease and in normal controls","volume":"97","author":"Forrest","year":"1999","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.amjcard.2012.06.014_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1164\/rccm.200412-1684OC","article-title":"Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy","volume":"172","author":"Girgis","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s004080000064","article-title":"High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy","volume":"179","author":"Ozkan","year":"2001","journal-title":"Lung"},{"key":"10.1016\/j.amjcard.2012.06.014_bib23","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1378\/chest.120.5.1562","article-title":"Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension","volume":"120","author":"Rubens","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2012.06.014_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1378\/chest.06-0682","article-title":"Endothelin-1\/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension","volume":"131","author":"Montani","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2012.06.014_bib25","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1378\/chest.128.4.2355","article-title":"von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension","volume":"128","author":"Kawut","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2012.06.014_bib26","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1378\/chest.114.5.1276","article-title":"Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension","volume":"114","author":"Lopes","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2012.06.014_bib27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1164\/rccm.200301-147OC","article-title":"Oxidative stress in severe pulmonary hypertension","volume":"169","author":"Bowers","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib28","doi-asserted-by":"crossref","first-page":"H2659","DOI":"10.1152\/ajpheart.00953.2007","article-title":"Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2) 27 rat","volume":"294","author":"DeMarco","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.amjcard.2012.06.014_bib29","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1164\/ajrccm.151.5.7735624","article-title":"Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension","volume":"151","author":"Humbert","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1440-1843.2006.00821.x","article-title":"Increased plasma monocyte chemoattractant protein\u20131 level in idiopathic pulmonary arterial hypertension","volume":"11","author":"Itoh","year":"2006","journal-title":"Respirology"},{"key":"10.1016\/j.amjcard.2012.06.014_bib31","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","article-title":"Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension","volume":"122","author":"Soon","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2012.06.014_bib32","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1378\/chest.10-1146","article-title":"Osteopontin in patients with idiopathic pulmonary hypertension","volume":"139","author":"Lorenzen","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2012.06.014_bib33","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jacc.2008.12.038","article-title":"C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension","volume":"53","author":"Quarck","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2012.06.014_bib34","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1164\/rccm.200802-235OC","article-title":"Growth differentiation factor\u201315 in idiopathic pulmonary arterial hypertension","volume":"178","author":"Nickel","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib35","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1164\/ajrccm.164.6.2104033","article-title":"Increased lipid peroxidation in patients with pulmonary hypertension","volume":"164","author":"Cracowski","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib36","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.freeradbiomed.2004.11.033","article-title":"Oxidant stress but not thromboxane decreases with epoprostenol therapy","volume":"38","author":"Robbins","year":"2005","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-2143(98)90020-8","article-title":"Pulmonary hypertension and inflammation","volume":"132","author":"Tuder","year":"1998","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00408-010-9232-9","article-title":"CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival","volume":"188","author":"Heresi","year":"2010","journal-title":"Lung"},{"key":"10.1016\/j.amjcard.2012.06.014_bib39","doi-asserted-by":"crossref","DOI":"10.1378\/chest.11-1267","article-title":"Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension","author":"Cracowski","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2012.06.014_bib40","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0002-8703(98)70041-9","article-title":"Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction","volume":"135","author":"Maeda","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2012.06.014_bib41","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(00)02060-2","article-title":"Treatment of heart failure guided by plasma aminoterminal BNP (N-) concentration","volume":"355","author":"Troughton","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2012.06.014_bib42","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0735-1097(01)01490-5","article-title":"Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: response to iloprost inhalation","volume":"38","author":"Wiedemann","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2012.06.014_bib43","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1164\/rccm.200510-1545OC","article-title":"Brain natriuretic peptide is a prognostic parameter in chronic lung disease","volume":"173","author":"Leuchte","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib44","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1164\/rccm.200308-1142OC","article-title":"Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension","volume":"170","author":"Leuchte","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib45","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jacc.2003.09.051","article-title":"Clinical significance of brain natriuretic peptide in primary pulmonary hypertension","volume":"43","author":"Leuchte","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2012.06.014_bib46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0735-1097(97)00452-X","article-title":"Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension","volume":"31","author":"Nagaya","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2012.06.014_bib47","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1378\/chest.128.4.2368","article-title":"Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension","volume":"128","author":"Leuchte","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2012.06.014_bib48","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.CIR.102.8.865","article-title":"Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension","volume":"102","author":"Nagaya","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2012.06.014_bib49","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1378\/chest.129.5.1313","article-title":"Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension","volume":"129","author":"Fijalkowska","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2012.06.014_bib50","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1378\/chest.06-1758","article-title":"N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension","volume":"131","author":"Leuchte","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2012.06.014_bib51","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2012.06.014_bib52","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2012.06.014_bib53","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jacc.2008.08.059","article-title":"Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial","volume":"52","author":"Jais","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2012.06.014_bib54","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0735-1097(02)02059-4","article-title":"Plasma brain natriuretic peptide concentration: impact of age and gender","volume":"40","author":"Redfield","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2012.06.014_bib55","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.CIR.0000084544.54513.E2","article-title":"Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension","volume":"108","author":"Torbicki","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2012.06.014_bib56","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/PAT.0b013e328343762d","article-title":"Sensitive and high sensitivity next generation cardiac troponin assays: more than just a name","volume":"43","author":"Christenson","year":"2011","journal-title":"Pathology"},{"key":"10.1016\/j.amjcard.2012.06.014_bib57","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1042\/CS20100014","article-title":"High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension","volume":"119","author":"Filusch","year":"2010","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.amjcard.2012.06.014_bib58","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1183\/09031936.00067011","article-title":"Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension","volume":"39","author":"Heresi","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjcard.2012.06.014_bib59","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1164\/rccm.200712-1876OC","article-title":"Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension","volume":"177","author":"Forfia","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib60","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1183\/09031936.00070209","article-title":"Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension","volume":"35","author":"Sztrymf","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjcard.2012.06.014_bib61","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1172\/JCI102008","article-title":"An estimation of hepatic blood flow and splanchnic oxygen consumption in heart failure","volume":"27","author":"Myers","year":"1948","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjcard.2012.06.014_bib62","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0002-9343(61)90093-6","article-title":"Alterations in indices of liver function in congestive heart failure with particular reference to serum enzymes","volume":"30","author":"Richman","year":"1961","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib63","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2466-10-22","article-title":"Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension","volume":"10","author":"Takeda","year":"2010","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib64","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"Benza","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2012.06.014_bib65","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1161\/CIRCULATIONAHA.107.719500","article-title":"Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension","volume":"117","author":"Shah","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2012.06.014_bib66","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/ajrccm.160.2.9812078","article-title":"Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension","volume":"160","author":"Nagaya","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib67","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1164\/rccm.201001-0007OC","article-title":"Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension","volume":"182","author":"Heresi","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjcard.2012.06.014_bib68","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1006\/bbrc.2002.6678","article-title":"The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification","volume":"292","author":"Issaq","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.amjcard.2012.06.014_bib69","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/pmic.200500510","article-title":"Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension","volume":"6","author":"Abdul-Salam","year":"2006","journal-title":"Proteomics"},{"key":"10.1016\/j.amjcard.2012.06.014_bib70","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1164\/rccm.200703-499OC","article-title":"Proteomics of transformed lymphocytes from a family with familial pulmonary arterial hypertension","volume":"177","author":"Meyrick","year":"2008","journal-title":"Am J Respir Crit Care Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914912015457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914912015457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:24:39Z","timestamp":1757571879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914912015457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0002914912015457"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2012.06.014","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Potential of Biomarkers in Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2012.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}